- Home
- SNES vs ALXO Comparison
SNES vs ALXO Comparison
Compare SNES & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- ALXO
- Stock Information
- Founded
- SNES 2004
- ALXO 2015
- Country
- SNES United States
- ALXO United States
- Employees
- SNES N/A
- ALXO N/A
- Industry
- SNES Agricultural Chemicals
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- ALXO Health Care
- Exchange
- SNES Nasdaq
- ALXO Nasdaq
- Market Cap
- SNES 21.0M
- ALXO 24.0M
- IPO Year
- SNES 2016
- ALXO 2020
- Fundamental
- Price
- SNES $4.67
- ALXO $0.64
- Analyst Decision
- SNES Strong Buy
- ALXO Strong Buy
- Analyst Count
- SNES 1
- ALXO 6
- Target Price
- SNES $10.00
- ALXO $3.30
- AVG Volume (30 Days)
- SNES 195.8K
- ALXO 563.3K
- Earning Date
- SNES 08-07-2025
- ALXO 08-12-2025
- Dividend Yield
- SNES N/A
- ALXO N/A
- EPS Growth
- SNES N/A
- ALXO N/A
- EPS
- SNES N/A
- ALXO N/A
- Revenue
- SNES $2,093,000.00
- ALXO N/A
- Revenue This Year
- SNES $130.53
- ALXO N/A
- Revenue Next Year
- SNES $80.00
- ALXO N/A
- P/E Ratio
- SNES N/A
- ALXO N/A
- Revenue Growth
- SNES 36.89
- ALXO N/A
- 52 Week Low
- SNES $1.30
- ALXO $0.40
- 52 Week High
- SNES $6.24
- ALXO $2.79
- Technical
- Relative Strength Index (RSI)
- SNES 46.89
- ALXO 57.73
- Support Level
- SNES $4.47
- ALXO $0.60
- Resistance Level
- SNES $6.24
- ALXO $0.69
- Average True Range (ATR)
- SNES 0.41
- ALXO 0.06
- MACD
- SNES -0.13
- ALXO 0.00
- Stochastic Oscillator
- SNES 19.03
- ALXO 63.95
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.